EMEA-000309-PIP06-21

Table of contents

Key facts

Invented name
RoActemra
Active substance
tocilizumab
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0466/2021
PIP number
EMEA-000309-PIP06-21
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of systemic sclerosis
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Roche Registration GmbH

E-mail: info.paediatrics@roche.com
Tel. +41 616879411

Decision type
RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)

Decision

Related content

How useful was this page?

Add your rating